TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22052619

Group type: EXPERIMENTAL
Intervention: Temozolomide 200 mg/m(2) orally for 7 days every 4 weeks (methylated MGMT - mMGMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Temozolomide 100 mg/m(2) orally for 14 days followed by 200 mg/m(2) orally for 7 days every 6 weeks (unmethylated MGMT - unMGMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall cohort (both mMGMT and unMGMT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Patients with high HCT-CI scores
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bone marrow blast count <50% at screening
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) among responders
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Duration of response among responders
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Induction deaths (ID)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hematological toxicities
Number of subjects: 36
Study: 22052690

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (720 EI.U of HAV and 20 µg of HBsAg)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Monovalent hepatitis B vaccine (additional dose)
Number of subjects: 306
Study: 22052917

Group type: EXPERIMENTAL
Intervention: MultiStem 20 million
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MultiStem 50 million
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MultiStem 100 million
Number of subjects: 25

Group type: COMPARATOR
Intervention: Registry control group
Number of subjects: 25
Study: 22054035

Group type: EXPERIMENTAL
Intervention: COPD subjects with exacerbations within 30 days of the 3-month visit
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: COPD subjects
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 201
Study: 22054223

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (BOTOX®)
Number of subjects: 609
Study: 22054243

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22055846

Group type: EXPERIMENTAL
Intervention: Ifosfamide and cisplatin sandwiched with RT
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ifosfamide alone sandwiched with RT
Number of subjects: 27
Study: 22056301

Group type: EXPERIMENTAL
Intervention: Latest generation wide-angle, high-definition colonoscopes
Number of subjects: 1256

Group type: COMPARATOR
Intervention: Routine equipment (mixed older technology endoscopes)
Number of subjects: 1256
Study: 22056381

Group type: EXPERIMENTAL
Intervention: IL-12 treatment
Number of subjects: 0
Study: 22056644

Group type: EXPERIMENTAL
Intervention: High-dose immunosuppressive therapy (HDIT) followed by autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 26
Study: 22057876

Group type: EXPERIMENTAL
Intervention: Markers of plaque instability (MPO, MRP-8/14, PAPP-A, CRP)
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: MPO, MRP-8/14, CRP
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control group (normal and high-sensitivity cardiac troponin T)
Number of subjects: 398
Study: 22058200

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/day (days 1-21 of each 28-day cycle) and dexamethasone (40 mg/day on days 1, 8, 15, and 22) for up to 12 months
Number of subjects: 33
Study: 22058217

Group type: EXPERIMENTAL
Intervention: CD20-positive patients
Number of subjects: 172

Group type: COMPARATOR
Intervention: CD20-negative patients
Number of subjects: 172
Study: 22058220

Group type: EXPERIMENTAL
Intervention: Telomere length measured by automated multicolor flow fluorescence in situ hybridization in peripheral blood leukocyte subsets.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lymphocytes alone for clinical screening.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Flow fluorescence in situ hybridization for telomere length measurement.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Longitudinal follow up of dyskeratosis congenita patients.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Age-adjusted telomere length values.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Telomere length measurement.
Number of subjects: 65
Study: 22058224

Group type: EXPERIMENTAL
Intervention: Platelet count in the first quartile on treatment day 33
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Neutrophil count above the median on day 8
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Platelet counts after induction treatment
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Minimal residual disease-based risk group distribution
Number of subjects: 256
Study: 22058223

Group type: EXPERIMENTAL
Intervention: Tandem transplants (double autologous transplant or a single autologous transplant followed by an allogeneic transplant)
Number of subjects: 80
Study: 22067102

Group type: EXPERIMENTAL
Intervention: Twice daily insulin regimen with long acting insulin analogue (LAIA) at dinner
Number of subjects: 18

Group type: COMPARATOR
Intervention: Three times daily insulin regimen (standard TID regimen)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Twice daily insulin regimen with LAIA at dinner
Number of subjects: 18
Study: 22067397

Group type: EXPERIMENTAL
Intervention: Ridaforolimus 12.5 mg administered as a 30-minute intravenous infusion once daily for 5 days every 2 weeks
Number of subjects: 212
Study: 22067400

Group type: EXPERIMENTAL
Intervention: Wait-and-see policy (cCR group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pathologic complete response (pCR group)
Number of subjects: 21
Study: 22067707

Group type: EXPERIMENTAL
Intervention: SIPP (Screening Inventory of Psychosocial Problems) screening procedure
Number of subjects: 268
Study: 22068254

Group type: EXPERIMENTAL
Intervention: Metreleptin treatment (subcutaneous injections once or twice daily)
Number of subjects: 55
Study: 22068586

Group type: EXPERIMENTAL
Intervention: ABCA3 mutations identified in patients
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Functional studies of p.D253H and p.T1173R mutations
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: p.T1173R mutation
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mortality and disease progression
Number of subjects: 47
Study: 22068813

Group type: EXPERIMENTAL
Intervention: Balanced diet (55 En% carbohydrates, 30 En% fat, 15 En% proteins) and exercise therapy once a week
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Balanced diet and exercise therapy
Number of subjects: 453
Study: 22069451

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for children ≤5 years old, duration of 6 months.
Number of subjects: 184
Study: 22069461

Group type: EXPERIMENTAL
Intervention: Seated video gaming
Number of subjects: 282
Study: 22070930

Group type: EXPERIMENTAL
Intervention: Toca 511 (non-lytic retroviral replicating vector)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toca 511
Number of subjects: 0
Study: 22071596

Group type: EXPERIMENTAL
Intervention: Afatinib 50 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Afatinib 20-50 mg/day
Number of subjects: 12
Study: 22073145

Group type: EXPERIMENTAL
Intervention: Septic shock patients (n = 9)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Septic rats with early death (n = 6)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Septic rats without early death (n = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham-operated rats (n = 8)
Number of subjects: 19
Study: 22074178

Group type: EXPERIMENTAL
Intervention: 6 g PinnoThin TAG
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 3 g PinnoThin TAG
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (milk fat)
Number of subjects: 67
Study: 22074614

Group type: EXPERIMENTAL
Intervention: Integrated primary care network for prevention and management of cardiometabolic risk (PCMR)
Number of subjects: 3000
Study: 22074813

Group type: EXPERIMENTAL
Intervention: Stimulant + Parent Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulant + Antipsychotic (Risperidone) + Parent Training
Number of subjects: 0
Study: 22075451

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stents (BES)
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Durable polymer sirolimus-eluting stents (SES)
Number of subjects: 1707
Study: 22075481

Group type: EXPERIMENTAL
Intervention: Bronchoscopic thermal vapour ablation (BTVA)
Number of subjects: 44
Study: 22075927

Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve (TPV) implantation with the Melody valve
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patients with MSF
Number of subjects: 150
Study: 22076476

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 48
Study: 22077194

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous antibiotics
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Postoperative systemic antibiotic therapy (68.7% of patients)
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Postoperative hematomas
Number of subjects: 1744

Group type: EXPERIMENTAL
Intervention: Povidone-iodine for topical antisepsis (used by sites with infection rates >5%)
Number of subjects: 1744
Study: 22078072

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30)
Number of subjects: 496
Study: 22078932

Group type: EXPERIMENTAL
Intervention: Linifanib 0.25 mg/kg/day
Number of subjects: 53
Study: 22078984

Group type: EXPERIMENTAL
Intervention: Abnormal %VLFI (>4%)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Male gender, increased body mass index, ambulatory systolic BP
Number of subjects: 428

Group type: COMPARATOR
Intervention: Normotensive subjects
Number of subjects: 428
Study: 22079051

Group type: EXPERIMENTAL
Intervention: Single Shot 3D-CRT Partial Breast Irradiation (SSPBI) with a dose of 21 Gy
Number of subjects: 64
Study: 22079305

Group type: EXPERIMENTAL
Intervention: rtPCR
Number of subjects: 227

Group type: COMPARATOR
Intervention: Culture
Number of subjects: 227
Study: 22079876

Group type: EXPERIMENTAL
Intervention: Intramuscular infusion of a combination cell product
Number of subjects: 26
Study: 22079961

Group type: EXPERIMENTAL
Intervention: Subthreshold diode laser MicroPulse (SDM)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg bevacizumab (BCZ)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 52
Study: 22080223

Group type: EXPERIMENTAL
Intervention: Individuals with SBP ≤ 140 mmHg
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Individuals with orthostatic hypotension
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Individuals with well-controlled BP (SBP < 140 mmHg)
Number of subjects: 994
Study: 22080332

Group type: EXPERIMENTAL
Intervention: RVI detected by cardiac magnetic resonance
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: High RV myocardial mass
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Low Thrombolysis In Myocardial Infarction flow before angioplasty
Number of subjects: 450

Group type: COMPARATOR
Intervention: Major adverse cardiac event (composite of death, reinfarction, and congestive heart failure)
Number of subjects: 450
Study: 22080707

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) A1c test
Number of subjects: 237
Study: 22080838

Group type: EXPERIMENTAL
Intervention: Genome-wide significant locus on chromosome 19q13 (rs7937)
Number of subjects: 3499

Group type: EXPERIMENTAL
Intervention: Genotyping of SNP rs7937 in 2859 subjects from ICGN
Number of subjects: 3499

Group type: EXPERIMENTAL
Intervention: Genotyping of SNP rs2604894 in 2859 subjects from ICGN
Number of subjects: 3499
Study: 22081446

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scanning
Number of subjects: 489

Group type: COMPARATOR
Intervention: Radiography
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: CT scanning
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: CT scanning and Radiography
Number of subjects: 489
Study: 22082029

Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) cultured in CellGenix DC media containing 2% human AB serum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) harvested using recombinant trypsin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) preserved with an infusible cryomedia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dendritic cells (DCs) activated for 16 hours with LPS and IFN-γ
Number of subjects: 0
Study: 22082722

Group type: EXPERIMENTAL
Intervention: Sex with both men and women (AAWSWM)
Number of subjects: 196
Study: 22083160

Group type: EXPERIMENTAL
Intervention: Hutchinson-Gilford progeria syndrome patients
Number of subjects: 0
Study: 22084160

Group type: EXPERIMENTAL
Intervention: Partial detachment of one-third or less of the graft surface area (n = 16; group 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Partial detachment of more than one-third of the graft surface area (n = 8; group 2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Graft positioned upside down (n = 4; group 3)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Free-floating Descemet roll in the host anterior chamber (n = 8; group 4)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall graft detachment (partial or complete)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Detachment causes
Number of subjects: 150
Study: 22086847

Group type: EXPERIMENTAL
Intervention: PET/CT imaging at 12 weeks after CRT completion
Number of subjects: 99

Group type: COMPARATOR
Intervention: Clinical assessment at 12 weeks after CRT completion
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Combined PET/CT and clinical assessment
Number of subjects: 99
Study: 22086881

Group type: EXPERIMENTAL
Intervention: High-dose calcium channel blockade as monotherapy or combination therapy
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Idiopathic PAH/familial PAH
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: PAH associated with congenital heart disease
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Older age at diagnosis
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Higher pulmonary vascular resistance index, lower-weight z scores, familial PAH
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Acute vasoreactivity
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Lower brain natriuretic peptide
Number of subjects: 216
Study: 22087267

Group type: EXPERIMENTAL
Intervention: Inactivated, monovalent, non-adjuvanted pandemic (H1N1) 2009 vaccine
Number of subjects: 1052
Study: 22087555

Group type: EXPERIMENTAL
Intervention: Treatment-as-usual at inpatient family clinics
Number of subjects: 102

Group type: COMPARATOR
Intervention: Community parents (n = 439)
Number of subjects: 102
Study: 22088584

Group type: EXPERIMENTAL
Intervention: Garcinia cambogia-derived HCA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22088784

Group type: EXPERIMENTAL
Intervention: Positioning (three different positions for 4 hours each)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Positioning (before and after feeding)
Number of subjects: 29
Study: 22088989

Group type: EXPERIMENTAL
Intervention: Crizotinib (dual MET/ALK inhibitor)
Number of subjects: 3
Study: 22089184

Group type: EXPERIMENTAL
Intervention: Multi Wave Animator (MWA) tool used for dynamic visualization of hemodynamic and ventilator data during cardiac arrest and resuscitation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video analysis of cardiac arrest and resuscitation events using MWA.
Number of subjects: 0
Study: 22089462

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted influenza A H1N1/2009 vaccine
Number of subjects: 237
Study: 22090362

Group type: EXPERIMENTAL
Intervention: PD 0332991 at 125 mg once daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: PD 0332991
Number of subjects: 41
Study: 22090469

Group type: EXPERIMENTAL
Intervention: Glycemic Index (GI) of breakfast meals
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Incremental Area Under the Curve (iAUC) after the OGTT
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Available Carbohydrate (avCHO) content of breakfast meals
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fat, protein, dietary fiber, age, sex, and BMI
Number of subjects: 57
Study: 22092012

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 21
Study: 22093200

Group type: EXPERIMENTAL
Intervention: Adenosine diphosphate (ADP) receptor inhibitors
Number of subjects: 17000

Group type: EXPERIMENTAL
Intervention: Point-of-care platelet inhibition testing
Number of subjects: 17000

Group type: EXPERIMENTAL
Intervention: Quarterly reports to participating sites
Number of subjects: 17000
Study: 22093207

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599
Study: 22093206

Group type: EXPERIMENTAL
Intervention: Myeloperoxidase (MPO) measured at arrival with a cutpoint of 210 ng/mL
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Myeloperoxidase (MPO)
Number of subjects: 1018
Study: 22093210

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents (BES)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Comparison at 24 months
Number of subjects: 56
Study: 22093579

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for 12 weeks
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 879
Study: 22094934

Group type: EXPERIMENTAL
Intervention: Preoperative paclitaxel (80 mg/m²) and gemcitabine (1,200 mg/m²) with weekly trastuzumab for 6 cycles, followed by 1 year of trastuzumab and 5 years of hormone therapy if indicated.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Preoperative paclitaxel, gemcitabine, and trastuzumab (PGH) combination therapy.
Number of subjects: 53
Study: 22095114

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle intervention
Number of subjects: 401

Group type: COMPARATOR
Intervention: Hypoenergetic diet program
Number of subjects: 401
Study: 22095837

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 26
Study: 22096242

Group type: EXPERIMENTAL
Intervention: Lower baseline hemoglobin concentration
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Higher baseline systolic blood pressure
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 814
Study: 22097928

Group type: EXPERIMENTAL
Intervention: Cigarette-related pictures
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pleasant pictures (erotica and romance)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 35
Study: 22098110

Group type: EXPERIMENTAL
Intervention: Epoetin alpha (Erypo®) intravenously (300 U/kg)
Number of subjects: 12
Study: 22098628

Group type: EXPERIMENTAL
Intervention: Open-label component of the STEP-BD
Number of subjects: 3399

Group type: EXPERIMENTAL
Intervention: Demographic and clinical characteristics
Number of subjects: 3399
Study: 22098676

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 0
Study: 22100149

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks (Module A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC = 6), paclitaxel 200 mg/m2, and bevacizumab 15 mg/kg for 4 cycles (Module B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Maintenance erlotinib 150 mg daily and bevacizumab 15 mg/kg every 3 weeks (Module C)
Number of subjects: 48
Study: 22102646

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/day intravenous undiluted alanyl-glutamine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 88
Study: 22102709

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intensification therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Molecular remission
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Post-induction minimal residual disease detection
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Molecular remission after induction chemotherapy
Number of subjects: 39
Study: 22104457

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study: 22104544

Group type: EXPERIMENTAL
Intervention: %VLFI of 2.4%
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: %VLFI of 4%
Number of subjects: 832
Study: 22105591

Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg/d
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Posaconazole 600-800 mg/d
Number of subjects: 74
Study: 22105720

Group type: EXPERIMENTAL
Intervention: Oral 3-AP at 150 mg per dose
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous 3-AP at 100 mg
Number of subjects: 20
Study: 22105799

Group type: EXPERIMENTAL
Intervention: AOSLO imaging and functional testing
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: AOSLO imaging
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Functional testing (ffERG, mfERG, SD-OCT)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Anti-retinal antibody analysis
Number of subjects: 4
Study: 22105801

Group type: EXPERIMENTAL
Intervention: Monocular ACI7000PDT corneal inlay implantation
Number of subjects: 24
Study: 22105894

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate at a dose of 400 mg/day for 1 year after surgery
Number of subjects: 64
Study: 22106236

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid and pulsed dye laser
Number of subjects: 23
Study: 22106377

Group type: EXPERIMENTAL
Intervention: Supervised, on-site standard (10 h) dose of Road Tour training
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Supervised, on-site standard dose of Road Tour training with 4 h of subsequent booster training
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Self-administered, at-home standard dose of Road Tour training
Number of subjects: 681

Group type: COMPARATOR
Intervention: Supervised, on-site standard dose of attention control (crossword puzzles) training
Number of subjects: 681
Study: 22106730

Group type: EXPERIMENTAL
Intervention: Calcitriol ointment 3 microg/g applied twice daily on weekdays and clobetasol propionate spray 0.05% applied twice daily on weekends for up to 4 weeks
Number of subjects: 0
Study: 22106941

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 22108357

Group type: EXPERIMENTAL
Intervention: Patching or Bangerter filters
Number of subjects: 633